CN108779119B - 嘧啶及其变体、及其用途 - Google Patents

嘧啶及其变体、及其用途 Download PDF

Info

Publication number
CN108779119B
CN108779119B CN201780019534.0A CN201780019534A CN108779119B CN 108779119 B CN108779119 B CN 108779119B CN 201780019534 A CN201780019534 A CN 201780019534A CN 108779119 B CN108779119 B CN 108779119B
Authority
CN
China
Prior art keywords
group
equiv
compound
mixture
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780019534.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108779119A (zh
Inventor
R·C·霍利
P·易卜拉欣
A·P·福特
J·R·格沃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afferent Pharmaceuticals Inc
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of CN108779119A publication Critical patent/CN108779119A/zh
Application granted granted Critical
Publication of CN108779119B publication Critical patent/CN108779119B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780019534.0A 2016-03-25 2017-03-20 嘧啶及其变体、及其用途 Active CN108779119B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
US62/313,334 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (2)

Publication Number Publication Date
CN108779119A CN108779119A (zh) 2018-11-09
CN108779119B true CN108779119B (zh) 2022-02-08

Family

ID=59900805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780019534.0A Active CN108779119B (zh) 2016-03-25 2017-03-20 嘧啶及其变体、及其用途

Country Status (11)

Country Link
US (2) US10662162B2 (cg-RX-API-DMAC7.html)
EP (1) EP3433258B1 (cg-RX-API-DMAC7.html)
JP (1) JP6902045B2 (cg-RX-API-DMAC7.html)
KR (1) KR102377805B1 (cg-RX-API-DMAC7.html)
CN (1) CN108779119B (cg-RX-API-DMAC7.html)
AU (1) AU2017237929B2 (cg-RX-API-DMAC7.html)
CA (1) CA3018180C (cg-RX-API-DMAC7.html)
MA (1) MA44489A (cg-RX-API-DMAC7.html)
MX (1) MX384368B (cg-RX-API-DMAC7.html)
RU (1) RU2760733C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017165255A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
AU2017237929B2 (en) 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CA3044366A1 (en) 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
MX381790B (es) * 2016-12-20 2025-03-13 Afferent Pharmaceuticals Inc Sales cristalinas y polimorfos de un antagonista de p2x3.
CN117186068A (zh) 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
EP3964505B1 (en) * 2019-04-30 2025-10-15 Beijing Tide Pharmaceutical Co., Ltd. Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof
SG11202111960PA (en) * 2019-04-30 2021-12-30 Beijing Tide Pharmaceutical Co Ltd Method for treating endometriosis-associated pain by using diaminopyrimidine compound
EP3960179B1 (en) * 2019-04-30 2026-03-18 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
US12595261B2 (en) 2019-06-06 2026-04-07 Beijing Tide Pharmaceutical Co., Ltd. P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof
CN120058573B (zh) * 2025-04-29 2025-12-23 潍坊学院 一种1-三溴甲基磺酰基萘及其衍生物的合成方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
WO2000059893A1 (en) * 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
WO2005095359A1 (en) * 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
WO2007025899A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025925A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025900A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
WO2007025901A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
WO2017160569A1 (en) * 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116493A (pt) * 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
DK2343281T3 (en) * 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
JP5423679B2 (ja) * 2007-10-31 2014-02-19 日産化学工業株式会社 ピリダジノン化合物及びp2x7受容体阻害剤
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
US10195198B2 (en) * 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
AU2017237929B2 (en) 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953567A (en) * 1956-11-23 1960-09-20 Burroughs Wellcome Co 5-phenylmercaptopyrimidines and method
WO2000059893A1 (en) * 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
WO2005095359A1 (en) * 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
WO2007025899A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025925A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2007025900A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
WO2007025901A1 (en) * 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
WO2008104472A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof
WO2017160569A1 (en) * 2016-03-14 2017-09-21 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN108834412A (zh) * 2016-03-14 2018-11-16 传入制药公司 嘧啶及其变体、及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
(5-Arylthiopyrimidines. I. 2,4-Diamino Derivatives;ELVIRA A. FALCO et al.;《Journal of Organic Chemistry》;19610430;第1143-1146页 *
2 , 4-二氨基-5-取代苯胺基嘧啶类化合物的合成及抗菌活性;赵维璋等;《药学学报》;19871231;第541-544页 *
Identification and SAR of novel diaminopyrimidines. Part 1: The discoveryof RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain;David S. Carter et al.;《Bioorganic & Medicinal Chemistry Letters》;20090207;第1628-1631页 *
Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain;Alam Jahangir et al.;《Bioorganic & Medicinal Chemistry Letters》;20090204;1632-1635页 *
REGISTRY[online];Colimbus,Ohio,US;《REGISTRY》;19841116;90767-71-8 *

Also Published As

Publication number Publication date
US20200239421A1 (en) 2020-07-30
US11230532B2 (en) 2022-01-25
EP3433258B1 (en) 2023-07-19
AU2017237929A1 (en) 2018-09-13
CA3018180A1 (en) 2017-09-28
RU2018137032A3 (cg-RX-API-DMAC7.html) 2020-05-22
MX384368B (es) 2025-03-14
RU2018137032A (ru) 2020-04-27
RU2760733C2 (ru) 2021-11-30
JP2019510025A (ja) 2019-04-11
JP6902045B2 (ja) 2021-07-14
KR20180128015A (ko) 2018-11-30
BR112018069105A2 (pt) 2019-01-29
EP3433258A4 (en) 2019-10-30
EP3433258A1 (en) 2019-01-30
AU2017237929B2 (en) 2021-04-15
CN108779119A (zh) 2018-11-09
KR102377805B1 (ko) 2022-03-22
WO2017165255A1 (en) 2017-09-28
CA3018180C (en) 2024-02-20
MA44489A (fr) 2019-01-30
MX2018011622A (es) 2019-03-28
US10662162B2 (en) 2020-05-26
US20190055202A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US11230532B2 (en) Pyrimidines and variants thereof, and uses therefor
CN108834412B (zh) 嘧啶及其变体、及其用途
WO2022170802A1 (zh) 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
WO2021227906A1 (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
TWI577677B (zh) 作爲ttx-s阻斷劑之吡咯並吡啶酮衍生物
KR20150128722A (ko) 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드
CN106536503A (zh) 一种酪氨酸激酶抑制剂及其用途
JP7634083B2 (ja) 新規なピラゾール誘導体
HK1210178A1 (en) Substituted pyridopyrazines as syk inhibitors
CN104812755B (zh) 作为ttx‑s阻断剂的吡唑并吡啶衍生物
TW200815425A (en) 2,5-disubstituted piperidines
CN109563033B (zh) 脂族脯氨酰胺衍生物
CN114685453A (zh) 杂环脯氨酰胺衍生物
CN106749203B (zh) 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
CN109206360B (zh) 咔唑酰胺类衍生物或其盐及其制备方法和用途
CN112759541B (zh) 类吲哚衍生物及其用途
BR112018069105B1 (pt) Composto de pirimidina, composição e uso do mesmo
WO2025209562A1 (zh) 作为Nav1.8抑制剂的四氢呋喃吡啶酮类化合物
HK40117941A (en) Pharmaceutical composition for treating cancer, comprising anticancer agent and novel compound having inhibitory activity with respect to prostaglandin e2 receptors
HK40048952A (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
HK40061204B (en) Pyrazine derivative and application thereof in inhibiting shp2
HK40004688B (en) Bicyclic proline compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: new jersey

Patentee after: AFFERENT PHARMACEUTICALS Inc.

Address before: California, USA

Patentee before: AFFERENT PHARMACEUTICALS Inc.